Drug Trial Radar · NCT01328379
Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Sep 5, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
430
Actual
Start
Mar 2011
Primary completion
Apr 2012
Study completion Jul 2012
Sponsor
- Lead sponsor
- Acorda TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 4, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the safety and efficacy of a lower dose of dalfampridine extended release tablets compared to the currently approved dose in improving walking in Multiple Sclerosis (MS) patients.
Conditions
- Multiple Sclerosis
Interventions
Dalfampridine-ER 5mgDrug
5mg, twice daily
Dalfampridine-ER 10mgDrug
10mg, twice daily
PlaceboOther
placebo, twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Walking Speed Near Maximum Plasma Concentration at Steady State (CmaxSS) of Placebo and Dalfampridine-ER (5mg and 10mg), Using the Timed 25 Foot Walk (T25FW).Time frame: Baseline Visit 1 (double-blind study day 1) and approximately 3-4 hours post dose at Visit 3 (end of double-blind week 4)
Locations
70 sites in 1 country. Site status is shown where the registry gives one.
North Central Neurology Associates, PC
Cullman, Alabama
Phoenix Neurological Associates, Ltd
Phoenix, Arizona
Arizona Neurological Institute
Sun City, Arizona
Clinical Research Advantage Inc.
Tempe, Arizona
Sutter East Bay Physicians Medical Foundation
Berkeley, California
Neuro-Pain Medical Center, Inc.
Fresno, California
Loma Linda University Medical Center
Loma Linda, California
Collaborative NeuroScience Network, Inc.
Long Beach, California
University of California Davis Medical Center
Sacramento, California
Mount Sinai Rehabilitation Hospital
Hartford, Connecticut
Georgetown University Hospital
Washington D.C., District of Columbia
Neurology Associates, PA
Maitland, Florida
University of Miami School of Medicine, Dept. of Neurology
Miami, Florida
Neurological Associates
Pompano Beach, Florida
Neurologique Foundation, Inc.
Ponte Vedra, Florida
Negroski, Sutherland and Hanes Neurology
Sarasota, Florida
Suncoast Neuroscience Associates, Inc.
St. Petersburg, Florida
Tallahassee Neurological Clinic, PA
Tallahassee, Florida
Axiom Clinical Research of Florida
Tampa, Florida
The Multiple Sclerosis Center of Vero Beach
Vero Beach, Florida
Sheperd Center, Inc.
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Consultants in Neurology Ltd.
Northbrook, Illinois
Indiana University School of Medicine
Indianapolis, Indiana
Josephson Wallack Munshower Neurology, PC
Indianapolis, Indiana
Methodist Plaza Specialty
Des Moines, Iowa
Ruan Neurology Clinic and Research Center
Des Moines, Iowa
The University of Kansas Medical Center
Kansas City, Kansas
Associates in Neurology, PSC
Lexington, Kentucky
University of Maryland, Maryland Center for Multiple Sclerosis
Baltimore, Maryland
Lahey Clinic
Lexington, Massachusetts
Springfield Neurology Associates, LLC
Springfield, Massachusetts
Wayne State University
Detroit, Michigan
Advanced Neurology Specialists
Great Falls, Montana
Veterans Administration Sierra Neveda Health Care System
Reno, Nevada
Upstate Clinical Research, LLC
Albany, New York
NYU Langone Medical Center MS Comprehensive Care Center
New York, New York
Comprehensive Multiple Sclerosis Care Center at South Shore Neurologic Associates
Patchogue, New York
Island Neurological Associates, PC
Plainview, New York
University of Rochester Medical Center
Rochester, New York
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.